<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543672</url>
  </required_header>
  <id_info>
    <org_study_id>M11VOL</org_study_id>
    <nct_id>NCT01543672</nct_id>
  </id_info>
  <brief_title>Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously</brief_title>
  <acronym>VOLUMES</acronym>
  <official_title>VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of larger tumor volumes or ≥ 2 lung metastases simultaneously in lung cancer
      patient using Stereotactic Body Radiation Therapy (SBRT) in a mean-lung dose escalation
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I/II multicenter trial will be conducted in patients with medically inoperable with
      peripheral non small cell lung cancer (NSCLC) &gt; 5 cm without lymph node involvement (group A)
      or medically with ≥ 2 or more lung metastases (group B). Radiation pneumonitis is expected to
      be dose-limiting in these patients and there is evidence that the incidence is predicted by
      the mean lung dose (MLD). The MLD escalation will be performed separately in both patient
      groups, using a time-to-event continual reassessment method (TITE-CRM). All patients will
      receive 3-5 fractions SBRT to the lung tumor(s), with a minimum mean PTV dose ≥ 42 Gy.
      Fraction size may be downscaled based on the MLD constraint.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 22, 2011</start_date>
  <completion_date type="Actual">October 31, 2017</completion_date>
  <primary_completion_date type="Actual">October 31, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MLD</measure>
    <time_frame>4 years</time_frame>
    <description>The assessment of the maximum mean lung dose that can be safely treated with SBRT and that is associated with a 20% probability of the DLT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>loco-regional control</measure>
    <time_frame>4 years</time_frame>
    <description>Determine the local control and regional control as a function of the mean lung dose, the largest toxicity effects as a function of the MLD and the overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Determine the local control and regional control as a function of the mean lung dose, the largest toxicity effects as a function of the MLD and the overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>2 years</time_frame>
    <description>valuate the increase or decrease of physical discomfort.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Metastatic Lung Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escalate MLD in medically inoperable patients with tumors larger than 5 cm in diameter (primary or solitary metastases)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalate the MLD in patients with ≥ 2 lung metastases</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy (SBRT)</intervention_name>
    <description>3-5 fractions within 10-14 days</description>
    <arm_group_label>SBRT group A</arm_group_label>
    <other_name>Stereotactic Body Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy (SBRT)</intervention_name>
    <description>3-5 fractions per tumor within one treatment session or sequential within one month</description>
    <arm_group_label>SBRT group B</arm_group_label>
    <other_name>Stereotactic Body Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for group A and B:

          -  Weight loss &lt; 10% in the last three months.

          -  WHO-performance status ≤ 2

          -  Medical inoperable patients or patients refusing surgery.

          -  Chemotherapy is allowed in neoadjuvant and adjuvant setting, with exclusion of the
             period 4 weeks pre-SBRT and 6 weeks post-SBRT.

          -  Before patient registration, written informed consent must be given according to
             ICH/GCP, national and local regulations.

        Risk group A specification:

          -  NSCLC (Cytological or histological proven) patients with peripheral tumors &gt;5 cm with
             tumor staging cT2bN0M0 or cT3N0M0 (chest wall infiltration is no exclusion criteria,
             as long as the tumor diameter is &gt; 5 cm).

          -  Single peripheral lung metastasis in inoperable patients with a diameter of &gt; 5 cm. In
             case of first presentation of metastatic disease, cytological or histological proof is
             obligated.

          -  In patients without cytological or histological confirmation of NSCLC, a growing
             FDG-PET positive lesion (SUV &gt;5) is accepted if a contra-indication for invasive
             diagnostic examination (or refusal) is present.

        Risk group B specification:

          -  Patients with ≥ 2 simultaneous peripheral lung metastases ≤ 5 cm of any origin at any
             location in the lung.

          -  In case of first presentation of metastatic disease, cytological or histological proof
             is obligated. This is not necessary in case of a history of an already proven
             disseminated disease.

          -  Patients having ≥ 2 peripheral lung metastases without unacceptable dose overlap.

        Exclusion Criteria:

          -  Patients with central tumors

          -  Pancoast tumors

          -  Prior radiotherapy treatment to the thorax

          -  Patients receiving any systemic treatment during SBRT

          -  Pregnant patients

          -  Patients previously treated with adriamycin agents in case of heart involvement within
             the treatment field.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heike Peulen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beaumont Hospital, Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University/ Kimmel Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>PA 19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prinses Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>DE-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NKI-AVL</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung</keyword>
  <keyword>SBRT</keyword>
  <keyword>MLD</keyword>
  <keyword>toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

